(0.22%) 5 142.75 points
(0.21%) 38 523 points
(0.29%) 17 898 points
(-0.56%) $83.38
(1.98%) $1.961
(-0.03%) $2 346.60
(0.25%) $27.61
(0.89%) $930.30
(-0.20%) $0.933
(-0.23%) $11.00
(-0.30%) $0.798
(1.08%) $92.86
@ $109.96
发出时间: 27 Apr 2024 @ 03:49
回报率: -0.45%
上一信号: Apr 26 - 22:04
上一信号:
回报率: 1.46 %
Live Chart Being Loaded With Signals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
今日成交量 | 476 129 |
平均成交量 | 605 514 |
市值 | 6.82B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $4.16 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.94 |
ATR14 | $4.06 (3.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Gala Renee D | Sell | 1 736 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 1 236 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 700 | Ordinary Shares |
2024-03-07 | Carr Patricia | Sell | 1 768 | Ordinary Shares |
2024-03-05 | Gala Renee D | Sell | 3 622 | Ordinary Shares |
INSIDER POWER |
---|
43.49 |
Last 96 transactions |
Buy: 357 937 | Sell: 150 837 |
音量 相关性
Jazz Pharmaceuticals PLC 相关性 - 货币/商品
Jazz Pharmaceuticals PLC 财务报表
Annual | 2023 |
营收: | $3.83B |
毛利润: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2023 |
营收: | $3.83B |
毛利润: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2022 |
营收: | $3.66B |
毛利润: | $3.12B (85.23 %) |
EPS: | $-3.42 |
FY | 2021 |
营收: | $3.09B |
毛利润: | $2.65B (85.76 %) |
EPS: | $-5.52 |
Financial Reports:
No articles found.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。